Stimuvax BLP25 Liposome Vaccine Clinical Program Temporarily Suspended, Suspected Une
Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. announced that they have temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR). This decision was taken in alignment with the U.S...
More... |
All times are GMT -7. The time now is 11:54 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021